FMP

FMP

Enter

OVID - Ovid Therapeuti...

photo-url-https://financialmodelingprep.com/image-stock/OVID.png

Ovid Therapeutics Inc.

OVID

NASDAQ

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

1.18 USD

-0.01 (-0.847%)

About

ceo

Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collabo...

CIK

0001636651

ISIN

US6904691010

CUSIP

690469101

Address

1460 Broadway

Phone

646 661 7661

Country

US

Employee

40

IPO Date

May 5, 2017

OVID Financial Summary

CIK

0001636651

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

690469101

ISIN

US6904691010

Country

US

Price

1.18

Beta

0.39

Volume Avg.

170.29k

Market Cap

83.75M

Shares

-

52-Week

0.68-4.1

DCF

-0.3

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-2.88

P/B

-

Website

https://www.ovidrx.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest OVID News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep